Bright Angel Therapeutics
Ms. Blumstock brings over 25 years of experience in the life science sector, spanning from early to late stage investments. She is currently the founder and CEO of Diamond Therapeutics, a Toronto based biotech company focused on developing therapies for mental health. In prior roles, Judith was Executive Director, Corporate Development at TIAP, an early stage academic incubator in Toronto. Judith was a principal with Genesys Capital Partners, one of the largest Canadian venture firms focused on the life sciences industry. She was a partner with Royal Bank Capital Partners Life Sciences Fund and Director of Bio/pharmaceutical Research at Drug Royalty Corporation (now DRI Capital). Judith received an MBA in finance from Columbia Business School and BSc in Biology from the University of Toronto.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Bright Angel Therapeutics
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance,enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.